BiomX (NYSEAMERICAN:PHGE – Get Free Report) is expected to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect BiomX to post earnings of ($1.10) per share for the quarter.
BiomX Stock Up 2.9 %
BiomX stock opened at $0.61 on Thursday. The firm has a market cap of $11.06 million, a price-to-earnings ratio of -0.19 and a beta of 1.27. BiomX has a twelve month low of $0.48 and a twelve month high of $4.99.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of BiomX in a report on Wednesday, January 8th.
About BiomX
BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
Featured Articles
- Five stocks we like better than BiomX
- Short Selling – The Pros and Cons
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Stock Average Calculator
- Alphabet’s Officially In A Bear Market—Time To Buy?
- The Basics of Support and Resistance
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for BiomX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiomX and related companies with MarketBeat.com's FREE daily email newsletter.
